SLC5A2 and COVID-19: This study did not include other cardiometabolic medications, such as anticoagulants, glucagon-like peptide 1 (GLP1) agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors, that may impact outcomes of COVID-19 [35, 40].